Publications by authors named "Thomas Melby"

Claim this Profile
C
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib.
Jonathan Kay, Masayoshi Harigai, Josh Rancourt, Christina Dickson, Thomas Melby

RMD Open· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.
Richard B Lipton, Louise Lombard, Dustin D Ruff, John H Krege, Li Shen Loo, Thomas E Melby

J Headache Pain· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies.
Stuart Silverman, Bente L Langdahl, Saeko Fujiwara, Ken Saag, Nicola Napoli, Thomas E Melby

Calcif Tissue Int· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies.
Bente L Langdahl, Stuart Silverman, Saeko Fujiwara, Ken Saag, Nicola Napoli, Thomas E Melby

Bone· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Effects of Teriparatide or Zoledronic Acid on Bone Modeling- and Remodeling-Based Formation in the SHOTZ Study.
David W Dempster, Hua Zhou, Valerie A Ruff, Thomas E Melby, Jahangir Alam

J Bone Miner Res· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study.
David W Dempster, Hua Zhou, Robert R Recker, Jacques P Brown, Christopher P Recknor, Thomas E Melby

J Bone Miner Res· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
Matthias Oelke, François Giuliano, Simin K Baygani, Thomas Melby, Angelina Sontag

BJU Int· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Skin reactions in a phase 3 study of a testosterone topical solution applied to the axilla in hypogonadal men.
David Muram, Thomas Melby, Erin Alles Kingshill

Curr Med Res Opin· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.
Karl-Erik Andersson, William C de Groat, Kevin T McVary, Tom F Lue, Mario Maggi, Thomas Melby

Neurourol Urodyn· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure.
Xuefang Bai, Karen L Wilson, Jennifer E Seedorff, Douglas Ahrens, Justin Green, Thomas E Melby

Biochemistry· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy.
Thomas E Melby, Michael Despirito, Ralph A Demasi, Gabrielle Heilek, James A Thommes

AIDS· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV coreceptor use in heavily treatment-experienced patients: does it take two to tangle?
Thomas Melby

Clin Infect Dis· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.
Joseph J Eron, Roy M Gulick, John A Bartlett, Thomas Merigan, Roberto Arduino, Thomas Melby

J Infect Dis· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors.
E Randall Lanier, Mounir Ait-Khaled, Janna Scott, Chris Stone, Thomas Melby

Antivir Ther· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis